Servier and the Autonomous University of Barcelona (UAB), have signed a partnership agreement to speed up research into Parkinson’s disease, using a new method for small-molecule screening developed by Prof Salvador Ventura, group leader at the Biochemistry and Molecular Biology Department at the UAB.
Within the framework of this agreement, scientists from Servier will collaborate with Prof Ventura’s teams to further develop and identify chemical series capable of neutralizing the pathogenicity of alpha-synuclein, a protein which is of major importance, not only in Parkinson’s disease, but also in several other neurodegenerative diseases.
“The discovery of new drugs to treat neurodegenerative and neuropsychiatric diseases is a key focus for Servier as there remain many unmet needs for patients with these pathologies,“ states Ross Jeggo, Director of Neuropsychiatric Research at Servier.
Parkinson’s disease is the second most common neurodegenerative disease, after Alzheimer disease, and affects about 10 million people worldwide.*